Working... Menu

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) (GMMG-BIRMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02834364
Recruitment Status : Recruiting
First Posted : July 15, 2016
Last Update Posted : May 15, 2018
Array BioPharma
German Cancer Research Center
Coordinating Centre for Clinical Trials Heidelberg
University Hospital Heidelberg
Information provided by (Responsible Party):
Marc Raab, University of Heidelberg Medical Center

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : April 2019
  Estimated Study Completion Date : March 2021